India Contract Manufacturing Organization (CMO) Market Growth, Status, Outlook and Opportunities to 2026 - AMRI India Pvt. Ltd., Dr. Reddy’s Laboratories, Cadila Healthcare Limited, Cipla Ltd.

The “India Contract Manufacturing Organization (CMO) Market” Research Report 2021-2027 is an in-depth study of the market, along with an analysis of its key segments. The relationship is built through extensive primary and secondary research. In-depth market data is generated through interviews and data collection from industry experts and professionals. The study is a detailed document on key aspects of the markets including trends, segmentation, growth prospects, opportunities, challenges, and competitive analysis.

The Indian CMO market was valued at USD 10.51 billion in 2020, and it is expected to reach USD 27.80 billion by 2026, at a CAGR of 17.6%, during the period of 2021 - 2026.

Click the link to get a free Sample Copy of the Report: (Flat 25%)

https://www.marketinsightsreports.com/reports/05202906604/india-contract-manufacturing-organization-cmo-market-growth-trends-covid-19-impact-and-forecasts-2021-2026/inquiry?Source=MS&Mode=28

The research report is a compilation of key data with regards to the competitive landscape of this vertical and the multiple regions where the business has successfully established its position.

Top Companies in the India Contract Manufacturing Organization (CMO) Market: AMRI India Pvt. Ltd., Dr. Reddy’s Laboratories, Cadila Healthcare Limited, MSN Laboratories Pvt Ltd., Mylan Laboratories Ltd., Medipaams India Pvt Ltd., Cipla Ltd., Eisai Pharmaceuticals India Pvt Ltd., Delwis Healthcare Pvt Ltd., Maxheal Pharmaceuticals India Ltd., Rhydburg Pharmaceuticals Ltd., and Other.

Industry News and Update:

- Sep 2019 - Eisai Pharmaceuticals India Pvt Ltd and Mylan Pharmaceuticals Pvt Ltd entered into a marketing license agreement, to commercialize TECERIS, the innovator’s second brand of the anticancer agent, Eribulin mesylate (Eribulin), in India. TECERIS is likely to be manufactured and supplied by Eisai India and marketed by Mylan. This partnership was an important strategy for expanding the access of Eribulin, for the treatment of metastatic breast cancer (MBC) patients in India.

- Apr 2019 - The Cipla Ltd., launched Niveoli, India’s first extra-fine particle beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler for adults, targeting drug delivery to small airways. Niveoli is a proprietary Cipla inhaler, and the latest offering from Cipla in respiratory inhalation therapy that addresses an unmet need associated with obstructive airway diseases (OAD), such as asthma and chronic obstructive pulmonary disorder (COPD).

Key Market Trends:

Generic Medicine Under Solid Finished Dose Segment Holds the Significant Share in The Market

- The solid dose formulation segment is mainly dominating the finished dose segment in India, owing to lower manufacturing cost, patent compliance, and ease of maintenance. Solid dosage forms, such as tablets, pills, capsules, powders, etc., are among the most adopted products in the country. The growth of generics drugs is one of the major factors driving the growth of the segment and India is the largest exporter of generic drugs and accounts for approximately 20% of global exports by volume.

- Recently, the growing collaborations between the Indian and Chinese pharma companies are expected to expand the segment’s scope. The only significant area where the Chinese pharma industry is lagging is finished drugs in solid dose forms. Through the partnership with Indian companies, Chinese pharma companies are keen on acquiring expertise and capability to manufacture generic formulations locally. This is expected to grow the demand for the studied segment too.

- For instance, in August 2019, Dr. Reddy’s Laboratories (DRL) became the first Indian company to export generic drugs to China. Moreover, Indian drug companies are looking for more partnerships in this region. Most recently, in 2019, Sun Pharmaceutical Industries Ltd, India’s largest drug-maker, signed a licensing pact with China Medical System Holdings for two specialty drugs.

- Moreover, the increase in outsourcing value by big pharma companies drives the market. Additionally, IDMA estimates that drugs worth USD 85 billion will lose their patents and would be available for generic manufacturing from 2020 onward. This will further boost the production capabilities of Indian CMOs as the manufacturing of those drugs won’t be viable in other countries.

- Also, new global opportunities are being made by generic manufacturers producing modified versions of approved off-patent small-molecule drugs. These so-called super-generics offer a therapeutic advantage, distinguishing them from conventional generic drugs. For instance, India-based Ranbaxy Laboratories developed a once-a-day ciprofloxacin tablet and licensed it to Germany-based Bayer AG.

Ask for TOC and Report Description:

https://www.marketinsightsreports.com/reports/05202906604/india-contract-manufacturing-organization-cmo-market-growth-trends-covid-19-impact-and-forecasts-2021-2026?Source=MS&Mode=28

What are the market factors that are explained in the report?

-Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a India and regional scale.

-Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

–Analytical Tools: The India Contract Manufacturing Organization (CMO) Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porter’s five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

The research includes historic data from 2015 to 2021 and forecasts until 2026 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs.

Market Insights Reports
4893, Pepper drive, Harrisburg ,NC 28075,United States

Irfan Tamboli (Head of Sales)
Market Insights Reports
Phone: + 1704 266 3234 | Mob: +91-750-707-8687
sales@marketinsightsreports.com
irfan@marketinsightsreports.com

We also offer customization on reports based on specific client requirements:
1- Free country level analysis for any 5 countries of your choice.
2- Free competitive analysis of any 5 key market players.
3- Free 40 analyst hours to cover any other data points

This release was published on openPR.